SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, celebrates today with longstanding partner, Da...
The NDA is based on the results of the Phase 3 Clarity AD study and the Phase 2b clinical study, which demonstrated that lecanemab treatment showed a reduc...
GE HealthCare (Nasdaq: GEHC) is presenting three new global innovations – Intelligent Radiation Therapy (iRT), Auto Segmentation, and an updated Magn...
Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than February 2039. The allowed claims cover MN...
As a Siemens Healthineers company, Varian is working to connect the cancer care continuum to empower clinicians to deliver more efficient, more personalize...
Veeva Systems (NYSE: VEEV) today announced that Sanofi is implementing Veeva Vault QMS and Veeva Vault QualityDocs to modernize quality management across t...
UCB's expertise in macrocyclic peptide discovery, using its proprietary mRNA-display platform, ExtremeDiversity™, will aid Ariceum's discovery of t...
Phase II dose-finding trial met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardi...
Collaboration will leverage Bicycle Therapeutic’s synthetic peptides for the discovery and development of multiple targeted radioconjugates of the ...
Increasing localized access can provide faster results for patients while potentially improving patient outcomes Agreement aims to enable greater access...
Exothera Nucleic Acids, the world's first nucleic acid CRDMO to provide continuous RNA manufacturing services from early discovery up to commercial cGMP, a...
Pharma service provider further expands offerings for clinical development and manufacturing Already 14 customer fills completed in the first quarter of...
“We are thrilled to have established a partnership with Dr. Reddy’s while toripalimab’s global commercial network has been steadily expan...
Nicola Thompson, CEO of Amphista, said, "We are absolutely delighted with the progress and success of our collaboration with BMS. Our ability to deliver ou...
© 2025 Biopharma Boardroom. All Rights Reserved.
